Iovance Biotherapeutics
IOVA
126 hedge funds and large institutions have $1.07B invested in Iovance Biotherapeutics in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 19 closing their positions.
137% more call options, than puts
Call options by funds: $4.65M | Put options by funds: $1.96M
56% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 34
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
5.92% more ownership
Funds ownership: 86.94% → 92.86% (+5.9%)
3% more funds holding
Funds holding: 122 → 126 (+4)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
19% less capital invested
Capital invested by funds: $1.31B → $1.07B (-$247M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$47.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.6M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$12.1M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$54.2M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$16.7M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$9.35M |
| 4 |
QF
QVT Financial
New York
|
-$8.63M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$6.14M |
IOVA Hedge Fund Activity: Q2 2018 in Review
126 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2018, worth a combined $1.07B — down 19% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IOVA positions and 19 closed out — a net gain of 6 holders — while 53 added to existing stakes and 34 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $47.3M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $54.2M sold.
- 126 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2018, up from 122 in Q1 2018.
- Funds reported $1.07B of Iovance Biotherapeutics stock for Q2 2018, down 19% quarter-over-quarter.
- 25 funds opened new Iovance Biotherapeutics positions in Q2 2018 and 19 closed out, a net change of +6 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2018 was Broadfin Capital, an estimated $47.3M added.
- The largest Iovance Biotherapeutics seller in Q2 2018 was Consonance Capital Management, an estimated $54.2M sold.
Based on aggregated 13F filings for Q2 2018.